Merck, Hanwha sign pact for biosimilar candidate
The contract allows Merck, known as MSD outside the US and Canada, to conduct clinical development and manufacture the product. Merck will also get the rights to commercialize
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).